The Japanese Ministry of Health, Labour and Welfare on Thursday approved Genmab A/S’ (NASDAQ:GMAB) Tivdak (tisotumab vedotin) ...

Concurrently, Genmab is embroiled in a legal dispute with AbbVie Inc (NYSE:ABBV)., which has accused the company of misappropriating trade secrets related to antibody-drug conjugates. Genmab has ...

AbbVie will pay Danish antibody specialist Genmab $750 million upfront for rights to a series of drugs headed by epcoritamab, a bispecific antibody in development for non-Hodgkin’s lymphoma.

Also Read: AbbVie/Genmab’s Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway The trial included 502 patients, 101 of which were Japanese.

Micrograph of a diffuse large B cell lymphoma, AbbVie and partner Genmab have FDA approval for the lead drug in their $3.9 billion cancer partnership, with bispecific antibody Epkinly now cleared ...

Merck signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion.

Concurrently, Genmab is embroiled in a legal dispute with AbbVie Inc (NYSE:ABBV)., which has accused the company of misappropriating trade secrets related to antibody-drug conjugates. Genmab has ...

Genmab (GMAB) announced that the European Commission has granted marketing authorization for TIVDAK, an antibody-drug conjugate, as monotherapy ...